Table 4.

Reclassification analyses for a model containing mid-regional pro-atrial natriuretic peptide and mid-regional pro-adrenomedullin in addition to a clinical risk model with (A) and without (B) amino-terminal pro-B type natriuretic peptide for death at 4 years, utilizing the continuous version of the net reclassification improvement approach

MR-proANP and MR-proADM with NT-proBNP	All	Reclassified upwards	Reclassified downwards	NRI		P-value
(A)
Kaplan–Meier rate of event	31.1%	54.2%	18.6%
Expected number of event subjects	170	104	66	Among event subjects	22%	0.004
Expected number of non-event subjects	376	88	288	Among non-event subjects	53%	<0.001
				Overall (95% bootstrap CI)	75.5% (59.5–92.8%)	<0.001
MR-proANP and MR-proADM without NT-proBNP	All	Reclassified upwards	Reclassified downwards	NRI		P-value
(B)
Kaplan–Meier rate of event	30.9%	55.2%	17.9%
Expected number of event subjects	170	106	64	Among event subjects	25%	0.0013
Expected number of non-event subjects	380	86	294	Among non-event subjects	55%	<0.001
				Overall (95% bootstrap CI)	79.4% (62.6–96.3%)	<0.001